GLP 1 DRUGS
India to make drugs for diabetes, obesity under PLI by 2026, says report India plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a government official speaking to Reuters. These drugs, originally approved for diabetes treatment, are also used for ...
28 Jun, 2024, 04.23 PM ISTOzempic frenzy lures rich Indians to brave the gray market People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage...
19 Jun, 2024, 08.25 AM ISTNew study warns of serious side effects from popular weight loss drugs Wegovy and Ozempic, finds they may paralyse stomach A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis, characterized by delayed stomach emptying. The study, presented at Digestive Disease Week 2024, indicates a 30% higher ris...
27 May, 2024, 11.04 AM IST- ADVERTISEMENT
Biocon inks licensing, supply pact with South Korea's Handok for chronic weight management product Biocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio to address weight management needs and tapping into a USD 47 million market opportunity. Biocon said the total ...
24 May, 2024, 10.57 AM ISTWegovy should be treating more than just obesity A new analysis highlights the significant cardiovascular benefits of Novo Nordisk's obesity drug Wegovy, showing improvements regardless of weight loss amount. This challenges perceptions of GLP-1 drugs, suggesting they could be viewed more as heart...
18 May, 2024, 12.56 AM ISTSanofi introduces diabetes drug Soliqua in India Sanofi India has launched its diabetes drug Soliqua in India, a once-daily injectable combination drug containing insulin and GLP-1 receptor agonist lixisenatide. The medication is available at a therapy cost of Rs 1,850 per pen and is indicated for...
30 Apr, 2024, 01.25 PM ISTDr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in India Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife fo...
28 Apr, 2024, 08.50 AM IST‘Obese people should opt for a structured programme of diet, exercise & medication’ "Nothing comes without a downside. These molecules do produce significant nausea and vomiting in some people — to the extent that they have to discontinue the medication. Some may develop diarrhoea, some may have severe constipation. Others may not ...
27 Apr, 2024, 11.35 PM ISTBiocon partners Biomm to commercialise diabetes drug in Brazil Biocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop, manufacture, and supply the drug, while Biomm will obtain regulatory approval and commercialization in Brazi...
17 Apr, 2024, 08.42 PM ISTWeight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivot Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based company secured UK approval for the first generic version of liraglutide inje...
08 Apr, 2024, 09.25 AM ISTAdvancing stem cell therapy: The regulatory process to get to clinical trials Advancements in new drug and stem cell therapy can transform the treatment of many diseases, but development is complicated, takes years and is expensive. Here is how one can get the necessary approvals from regulators to start clinical trials.
04 Mar, 2024, 10.02 AM ISTEli Lilly could launch obesity drug in India next year, CEO says Eli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepbound in the US. The global market for GLP-1 receptor agonists, including Mounjaro, Wegovy, and Ozempic, is expect...
29 Feb, 2024, 07.49 PM ISTWhat other health conditions might weight-loss drugs treat? New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diabetes patients.
02 Jan, 2024, 05.13 PM ISTWeight-loss drugs: Who, and what, are they good for? The new drugs are known as GLP-1 agonists, which mimic the activity of a hormone that slows digestion and helps people feel full for longer. In clinical trials, people lost 15% to 20% of their body weight, depending on the drug. Nearly 120 million A...
02 Jan, 2024, 05.08 PM ISTIndiamart working with Novo Nordisk to halt illegal Wegovy sales The drugmaker's India legal team held discussions with Indiamart's top executives to develop a "framework" for regularly alerting the online marketplace about listings by counterfeiters in an effort to curtail illegal sales, the source said on condi...
18 Dec, 2023, 07.03 AM ISTWeight loss drugs not a threat to Nestle biz: CEO Mark Schneider Nestle CEO Mark Schneider has defended its strategy of building a lower-calorie product portfolio, stating that the threat of GLP-1 weight-loss drugs is less significant. The company now generates half of its revenue from coffee, pet care, and vitam...
14 Dec, 2023, 12.30 AM ISTMaker of Wegovy, Ozempic showers money on US obesity doctors Novo Nordisk, a Danish pharmaceutical company renowned for its diabetes medicines, is now positioning itself as the world's leading weight-loss company. The company aims to target the global population of 764 million people with obesity, with the Un...
02 Dec, 2023, 09.49 PM ISTDrug regulator halts production at 76 units over poor standards More than 75% of the firms have also been issued show cause notices, the people said. Out of the total samples drawn from these manufacturing units, 15.1% have so far been declared to be of not of standard quality (NSQ). The regulator is currently c...
23 Nov, 2023, 10.19 AM ISTHow well-off Brits still buy Ozempic online for weight loss The demand for the diabetes drug Ozempic, known for its weight-loss effects, has led to shortages in countries like Britain and the United States. A contrast in access reveals that those with means can purchase it online for weight loss, despite gov...
18 Nov, 2023, 05.05 PM ISTDr Reddy's gears up for weight loss drug study Dr Reddy's Laboratories has received approval from India's drug regulatory authority to conduct a bioequivalence study for the weight loss drug Semaglutide. The company had sought a waiver for the study and a Phase III clinical trial, but the SEC re...
18 Oct, 2023, 10.26 AM IST